DekaBank Deutsche Girozentrale Purchases 1,173 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

DekaBank Deutsche Girozentrale lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,030 shares of the company’s stock after acquiring an additional 1,173 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.12% of Medpace worth $14,459,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in MEDP. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Medpace by 2.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after acquiring an additional 148 shares in the last quarter. FORA Capital LLC acquired a new position in shares of Medpace during the first quarter worth $2,222,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Medpace by 355.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock valued at $1,090,000 after acquiring an additional 2,774 shares during the last quarter. Norden Group LLC boosted its holdings in shares of Medpace by 207.8% during the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock valued at $1,537,000 after acquiring an additional 3,385 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Medpace during the 1st quarter worth $5,179,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 2.1 %

NASDAQ:MEDP traded down $8.16 during trading hours on Friday, reaching $377.00. The company had a trading volume of 322,082 shares, compared to its average volume of 337,243. The business’s 50-day simple moving average is $403.18 and its two-hundred day simple moving average is $385.39. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $459.77. The firm has a market cap of $11.69 billion, a price-to-earnings ratio of 38.43, a P/E/G ratio of 2.00 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the business earned $1.93 EPS. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, equities analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. TD Cowen lowered their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Guggenheim decreased their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Truist Financial started coverage on Medpace in a research report on Thursday. They set a “hold” rating and a $415.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Medpace currently has an average rating of “Moderate Buy” and a consensus price target of $423.00.

Insider Buying and Selling at Medpace

In other news, Director Ashley M. Keating 1,300 shares of the stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Ashley M. Keating 1,300 shares of the company’s stock in a transaction dated Tuesday, July 30th. The was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 4,782 shares of Medpace stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the transaction, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,519 shares of company stock worth $5,765,631. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.